claim: SummerSlam is replaced by the WWE.
evidence: Fulranumab is a monoclonal antibody against nerve growth factor .. monoclonal antibody. monoclonal antibodies. nerve growth factor. nerve growth factor. It was designed for the treatment of pain .. Johnson & Johnson licensed the drug from Amgen in a deal valued at around USD 425 million in 2008 .. Johnson & Johnson. Johnson & Johnson. Amgen. Amgen. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator .. Johnson & Johnson. Johnson & Johnson. The company said the decision was based on `` strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab '' in osteoarthritic pain .